Kena A. Swanson

Best Publications

• Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

  Fernando P. Polack;Stephen J. Thomas;Nicholas Kitchin;Judith Absalon

  14076
  Citations

• Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.

  Edward E. Walsh;Robert W. Frenck;Ann R. Falsey;Ann R. Falsey;Nicholas Kitchin

  2629
  Citations

• COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses.

  Ugur Sahin;Alexander Muik;Evelyna Derhovanessian;Isabel Vogler

  2204
  Citations

• Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.

  Mark J. Mulligan;Kirsten E. Lyke;Nicholas Kitchin;Judith Absalon

  1672
  Citations

• Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.

  Unknown

  992
  Citations

• Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.

  Robert W Frenck;Nicola P Klein;Nicholas Kitchin;Alejandra Gurtman

  847
  Citations

• BNT162b vaccines protect rhesus macaques from SARS-CoV-2.

  Annette B. Vogel;Isis Kanevsky;Ye Che;Kena A. Swanson

  686
  Citations

• Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera

  Unknown

  678
  Citations

• Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults.

  Unknown

  676
  Citations

• Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.

  Emmanuel B. Walter;Kawsar R. Talaat;Charu Sabharwal;Alejandra Gurtman

  599
  Citations

• Neutralizing Activity of BNT162b2-Elicited Serum.

  Yang Liu;Jianying Liu;Hongjie Xia;Xianwen Zhang

  582
  Citations

• Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera.

  Xuping Xie;Yang Liu;Jianying Liu;Xianwen Zhang

  580
  Citations

• Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera.

  Alexander Muik;Ann-Kathrin Wallisch;Bianca Sänger;Kena A. Swanson

  527
  Citations

• SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.

  Ann R Falsey;Robert W Frenck;Edward E Walsh;Nicholas Kitchin

  373
  Citations

• BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.

  Jianying Liu;Yang Liu;Hongjie Xia;Jing Zou

  342
  Citations

• Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine

  Unknown

  244
  Citations

• Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2

  Unknown

  182
  Citations

• Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study.

  Unknown

  178
  Citations

• Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years

  Unknown

  175
  Citations

• RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study

  Edward E. Walsh;Robert Frenck;Ann R. Falsey;Nicholas Kitchin

  170
  Citations